Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Department of Justice
Boehringer Ingelheim
Deloitte
McKesson
Merck
Chinese Patent Office
Medtronic
Cipla
Fish and Richardson

Generated: April 24, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 012623

« Back to Dashboard

NDA 012623 describes FLAGYL, which is a drug marketed by Gd Searle Llc, Pfizer, and Baxter Hlthcare, and is included in five NDAs. It is available from one supplier. Additional details are available on the FLAGYL profile page.

The generic ingredient in FLAGYL is metronidazole hydrochloride. There are eighteen drug master file entries for this compound. Additional details are available on the metronidazole hydrochloride profile page.
Summary for 012623
Tradename:FLAGYL
Applicant:Gd Searle Llc
Ingredient:metronidazole
Patents:0
Therapeutic Class:Antibacterials
Formulation / Manufacturing:see details
Pharmacology for NDA: 012623
Ingredient-typeNitroimidazoles
Medical Subject Heading (MeSH) Categories for 012623
Suppliers and Packaging for NDA: 012623
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
FLAGYL metronidazole TABLET;ORAL 012623 NDA G.D. Searle LLC Division of Pfizer Inc 0025-1821 N 0025-1821-50
FLAGYL metronidazole TABLET;ORAL 012623 NDA G.D. Searle LLC Division of Pfizer Inc 0025-1821 N 0025-1821-31

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength250MG
Approval Date:Approved Prior to Jan 1, 1982TE:ABRLD:Yes

Profile for product number 003

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength500MG
Approval Date:Approved Prior to Jan 1, 1982TE:ABRLD:Yes

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Chubb
McKinsey
Citi
McKesson
Deloitte
Medtronic
Accenture
AstraZeneca
QuintilesIMS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.